Trial Profile

A clinical trial assessing ANK-101 in combination with pembrolizumab in patients with advanced solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tolododekin alfa (Primary)
Indications Solid tumours
Focus Adverse reactions
Acronyms KEYNOTE-E56

Most Recent Events

13 Nov 2023 According to Ankyra Therapeutics media release, combination study will proceed following first-in-human phase I clinical trial, which is starting in the first quarter of 2024.
14 Oct 2023 According to Ankyra Therapeutics media release, company plan to initiate a Phase 1 clinical study in humans in early 2024.
10 Oct 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com